RBC Europe’s Novavax NVAX Stock Holding History

RBC Europe’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,936	Closed	-$401K	–	969
2021 Q3	$401K	Buy	1,936 +325	+20%	+$71.6K	0.02%	214
2021 Q2	$342K	Hold	1,611	–	–	0.02%	240
2021 Q1	$292K	Buy	1,611 +1,440	+842%	+$287K	0.02%	244
2020 Q4	$19.1K	Sell	171 -210	-55%	-$22.3K	﹤0.01%	733
2020 Q3	$41.3K	Buy	381 +356	+1,424%	+$43.4K	﹤0.01%	507
2020 Q2	$2.08K	Sell	25 -139	-85%	-$5.32K	﹤0.01%	955
2020 Q1	$2.23K	Hold	164	–	–	﹤0.01%	905
2019 Q4	$653	Hold	164	–	–	﹤0.01%	1004
2019 Q3	$823	Hold	164	–	–	﹤0.01%	996
2019 Q2	$961	Sell	164 -1	-0.6%	-$8	﹤0.01%	1011
2019 Q1	$1.81K	Hold	165	–	–	﹤0.01%	998
2018 Q4	$6.06K	Buy	165 +50	+43%	+$1.94K	﹤0.01%	895
2018 Q3	$4.32K	Hold	115	–	–	﹤0.01%	977
2018 Q2	$3.08K	Hold	115	–	–	﹤0.01%	1025
2018 Q1	$4.82K	Buy	+115	New	+$4.62K	﹤0.01%	950

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

RBC Europe's NVAX Position: Q4 2021 in Review

RBC Europe sold out of Novavax (NVAX) in Q4 2021, closing a stake of 1,936 shares — an estimated $401K sold.

RBC Europe first reported a position in NVAX in Q1 2018 and held it in 15 quarters. The position peaked at $401K in Q3 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

RBC Europe reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 1,936 Novavax shares in Q4 2021, an estimated $401K.
RBC Europe first reported a position in Novavax in Q1 2018 and held it in 15 quarters.
RBC Europe's Novavax position peaked at $401K in Q3 2021.
429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.